The US Food and Drug Administration (FDA) has accepted for review the resubmitted supplemental Biologics License Application (sBLA) for Sanofi and Regeneron’s Dupixent (dupilumab) in chronic ...

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

Regeneron (NASDAQ:REGN) and Sanofi (NASDAQ:SNY) announced Friday that the U.S. FDA approved a label expansion for its asthma ...

Dupixent is a brand-name injection that doctors prescribe to treat certain conditions, including atopic dermatitis and asthma. Injection site reactions, such as pain, are common side effects of ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...